B

    Biomotion Sciences Ordinary Shares (SLXN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.36
    +0.00 (+0.72%)

    Market Cap: $2.06M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    33%(2/6)
    Avg Surprise
    -969.17%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.91
    Range$-0.91 - $-0.91
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-13.30-1361.5%
    60d ago$-13.30-1361.5%
    30d ago$-15.20-1570.3%
    7d ago$-1.52-67.0%
    Current$-0.91
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-0.67 - $-0.67
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-0.91---
    Jun 26
    Reported Aug 11
    		$-5.17$-2.12-143.87%Miss-19.7%
    Mar 26
    Reported May 15
    		$-8.50$-12.90+34.11%Beat-3221.6%
    Dec 25
    Reported Mar 17
    		$N/A$-11.20N/ABeat-
    Sep 25
    Reported Nov 12
    		$-28.80$-34.00+15.29%Beat+98.9%
    Jun 25
    Reported Aug 12
    		$-4.32$-0.21-1956.71%Miss-15001.7%
    Mar 25
    Reported May 13
    		$-0.26$0.00N/ABeat-395.0%
    Dec 24
    Reported Mar 18
    		$-3114.00$-147.00-2018.37%Miss-30981.6%
    Sep 24
    Reported Nov 14
    		$-2740.50$-148.50-1745.45%Miss-136321.3%
    Jun 24
    Reported Aug 13
    		$-0.03N/AN/ABeat-100.8%
    Mar 24
    Reported May 15
    		$-0.05N/AN/ABeat-101.3%
    Dec 23
    Reported Dec 31
    		$-10.02N/AN/ABeat-33496.0%
    Sep 23
    Reported Sep 30
    		$2.01N/AN/ABeat+9959.0%
    Jun 23
    Reported Jun 30
    		$3.70N/AN/ABeat+853.7%
    Mar 23
    Reported Mar 31
    		$3.90N/AN/ABeat+19584.0%
    Dec 22
    Reported Mar 31
    		$0.03N/AN/ABeat+250.0%
    Sep 22
    Reported Nov 14
    		$0.02N/AN/ABeat+200.0%
    Jun 22
    Reported Aug 15
    		$0.39N/AN/ABeat+3980.0%
    Mar 22
    Reported May 23
    		$-0.02N/AN/ABeat-100.0%
    Dec 21
    Reported Mar 31
    		$-0.02N/AN/ABeat-
    Sep 21
    Reported Nov 9
    		$-0.02N/AN/ABeat-
    Jun 21
    Reported Aug 16
    		$-0.01N/AN/ABeat-
    Mar 21
    Reported May 25
    		$-0.01$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-897.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.94xQuick Ratio0.94x
    Trading Statistics
    Beta-0.27Avg Volume565.47K
    52-Week High$77.7052-Week Low$0.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.39
    SMA 20$0.85
    SMA 50$1.85
    SMA 200$12.13
    EMA 10$0.48
    EMA 20$0.83
    EMA 50$2.05
    EMA 200$19.54

    MACD

    Line: -0.51Signal: -0.55Hist: 0.04

    ADX

    ADX: 50.6+DI: 7.2-DI: 34.5

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$0.48

    Bollinger Bands

    Upper Band$2.17
    Lower Band$-0.47
    %B Position30945%(Upper)
    Band Width0.31

    RSI (14-Day)

    Oversold
    19.5

    Momentum Oscillators

    Stoch %K0.7
    Stoch %D0.5
    Williams %R-98.9
    ROC (10d)-13.7%
    Momentum-0.06
    CCI (20d)-54.9
    MFI (14d)5.2

    Volatility Measures

    ATR (14d)$0.20(53.8%)
    StdDev (20d)0.66
    Hist Vol227.2%(High)

    Volume Flow

    VWAP$0.36
    OBV465.3M
    AD Line315.0B
    CMF (20d)-0.029

    Volume Metrics

    Avg Vol (20d)603.5K
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.65

    Pivot Points

    R3$0.41
    R2$0.39
    R1$0.38
    Pivot Point$0.36
    S1$0.35
    S2$0.33
    S3$0.32

    Advanced Oscillators

    TSI-58.12
    Ultimate Osc33.7
    KST-788.62

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$55,000$30,000$0$0$0$0$0$0$0$-72,000
    Cost of Revenue$0$0$3,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$55,000$30,000$0$0N/A$0$0$0N/A$-72,000
    Operating Expenses$3.68M$2.75M$4.41M$3.29M$2.28M$1.65M$1.90M$8.04M$1.39M$1.25M$1.73M$731,000
    R&D$2.21M$1.37M$3.38M$2.16M$1.02M$590,000$871,000$3.22M$766,000$961,000$1.26M$535,000
    SG&A$1.47M$1.38M$1.03M$1.14M$1.27M$1.06M$1.03M$4.82M$619,000$289,000$465,000$196,000
    Operating Income$-3,680,000$-2,749,000$-4,321,000$-3,292,000$-2,284,000$-1,650,000$-1,900,000$-8,036,000$-1,385,000$-1,250,000$-1,728,000$-731,000
    Interest Income$0$0$0$0$0$-85,000$0$0$0$0$33,000$0
    Interest Expense$0$-16,000$91,000$0$216,000$85,000$0$3.82M$102,000$168,000$43,000$72,000
    Income Before Tax$-3,551,000$-2,733,000$-4,412,000$-3,262,000$-2,500,000$-1,735,000$-1,746,000$-11,858,000$-1,487,000$-1,418,000$-1,674,000$-803,000
    Income Tax Expense$0$0$0$0$3,000$0$1,000$2,000$2,000$5,000$6,000$6,000
    Net Income$-3,551,000$-2,733,000$-4,412,000$-3,262,000$-2,503,000$-1,735,000$-1,747,000$-11,860,000$-1,489,000$-1,423,000$-1,728,000$-809,000
    EBITDA$-3,548,000$-2,747,000$-4,318,000$-3,288,000$-2,497,000$-1,646,000$-1,758,000$-11,836,000$-1,480,000$-1,410,000$-1,668,000$-721,000
    EBIT$-3,551,000$-2,749,000$-4,321,000$-3,292,000$-2,500,000$-1,650,000$-1,746,000$-11,858,000$-1,487,000$-1,418,000$-1,674,000$-731,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLXN

    News

    Silexion Therapeutics Received Notice of Delisting

    Silexion Therapeutics (SLXN) received a Nasdaq delisting notice on August 18, 2026, for failing to meet the $2.5 million shareholders' equity requirement, with a reported equity of $44,000 as of June 30, 2026. The company plans to appeal by August 25, 2026, or face suspension of trading and removal from Nasdaq. This information is based on an original SEC Filing.

    TradingView•8/21/26•
    Bearish

    [SCHEDULE 13D/A] Silexion Therapeutics Corp Amended Major Shareholder Report

    Moringa Sponsor, LP has filed an amended Schedule 13D/A for Silexion Therapeutics Corp (SLXN), reporting a 25% beneficial ownership, including shares issued from contested note conversions. Moringa Sponsor disputes the validity of these share issuances and has filed a claim seeking a declaration that the conversions are void and immediate repayment of the debt. The filing details various conversion events and highlights ongoing legal disputes regarding the promissory note.

    Stock Titan•8/20/26•
    Somewhat-Bearish

    Silexion Therapeutics (SLXN) draws new stake capped by warrant blockers

    Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has reported a beneficial ownership stake of 4.99% in Silexion Therapeutics (SLXN), totaling 286,866 Ordinary Shares. This stake includes shares held outright and those underlying various warrants, all subject to blocker provisions preventing beneficial ownership from exceeding specified thresholds like 4.99% or 9.99%. The filing highlights how these blocker provisions limit the immediate exercise of a larger number of warrant shares, keeping the reported ownership below certain caps.

    Stock Titan•8/19/26•
    Neutral

    Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts

    Silexion reported a net loss of $3.6 million for its second quarter, primarily due to increased research and development expenses as it advanced its lead drug candidate, SIL204. The company announced the initiation of a Phase 1b trial for SIL204 in patients with non-small cell lung cancer, marking a significant step in its clinical development. Despite the loss, Silexion highlighted its progress in bringing new therapies to patients.

    Moomoo•8/15/26•
    Neutral

    Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

    Silexion Therapeutics announced its Q2 2026 financial results, highlighting the successful transition of its drug candidate SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer in Israel and Germany. The company also reported new preclinical data supporting SIL204's immune-sensitizing properties and detailed financial actions taken to strengthen its balance sheet and maintain Nasdaq compliance.

    GlobeNewswire•8/15/26•
    Bullish

    Frequently Asked Questions About SLXN

    Does SLXN pay dividends?
    Biomotion Sciences Ordinary Shares (SLXN) does not currently pay a regular dividend.
    What is SLXN's market cap?
    Biomotion Sciences Ordinary Shares (SLXN) has a market capitalization of $2.06M with a current stock price of $0.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In